You are here

Imagin Medical Inc.

Listing Exchange: 
CSE
Status: 
Active
Industry: 
Technology
Symbol: 
IME
CSE Index: 
Currency: 

 

Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries.  The company's initial target is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and most costly cancer to treat due to greater than 50% recurrence rate. 

Imagin Medical is developing the i/Blue™ Imaging System to significantly improve surgeons’ ability to visualize cancerous cells and enable more accurate bladder cancer resection. Using innovative optic and light sensor technology, the i/Blue System combines the advantages of white and blue light cystoscopy with fluorescing contrast agents to simultaneously display white and blue light images on the surgical monitor, side-by-side, in real-time. Based on functional prototype demonstrations, leading urologists have indicated that this feature could make bladder cancer detection and removal more accurate and efficient, potentially reducing recurrence rates.

You are here

Imagin Medical Inc. (IME)

SEDAR Information

Company Info

Address
890 West Pender St., Suite 600
Vancouver, BC V6C 1J9
Canada
Phone
833-246-2446
Email
jvacha@imaginmedical.com
Website
http://www.imaginmedical.com
Listing date
Wednesday, February 24, 2016
Transfer Agent
Computershare Investor Services Inc.
Investor Relations
John Vacha
Email
jvacha@imaginmedical.com
Auditor
De Visser Gray

Advertisement

Publicité

Capitalization

Issued & Outstanding: 
8,917,013
Reserved for Issuance: 
2,501,790

Company Officers

E. James Hutchens, President & CEO
John Vacha, Chief Financial Officer (CFO)

Bulletins

26/10/2020

2020-1035 – Consolidation - Imagin Medical Inc. (IME)

Le 26 octobre/October 2020

Imagin Medical Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidation common shares for every twenty (20) pre-consolidation common shares.

As a result, the outstanding shares of the company will be reduced to approximately 8,917,013 common shares

The name and symbol will not change.

Advertisement

Publicité

Latest CSE News

Upcoming Events

2020-12-01-AfriLeaf-Inaugural-Annual-Conference_Website_1.png

AfriLeaf Biosciences’ Inaugural Annual Conference 2020

Tuesday, December 1, 2020 -
8:00am to 12:00pm
2020-12-01-Tech-Tuesday-Best-of-Autumn_Website_1.png

Tech Tuesdays

Tuesday, December 1, 2020 -
4:15pm to 5:00pm
Health-Tech-Thursdays_general_Website_2.png

Health Tech Thursdays

Thursday, December 3, 2020 -
1:15pm to 2:00pm